Updated on 18 August 2026
Paradigm-shifting healthtech solution dealing with the deadliest health condition worldwide
CEO at AiMorphous Healthtech
China (Hong Kong)
About
Thrombosis is the number 1 disease condition causing most death and debilitation. Most of the thrombotic events are avoidable if early detection and warning technology is available. Today’s healthcare system does not have such technology to predict the individualized risk with high accuracy and help manage the risk. With our novel tech, together with precise pharmaceutical intervention, future healthcare will experience better anti-thrombotic treatment with dramatic reduction in recurrent bleeding and thrombosis through breakthrough early blood biomarker and novel predictive AI modelling method, solving the decade-old technical difficulties in early detection and accurate individual risk prediction problem. Product range: reagent kit, software and hardware.
Project Location
- China (Hong Kong)
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Manufacturing
biotech, medical technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 25,000,001 to 50,000,000 USD
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Direct Equity Investment
Preferred Financing Model
- Equity
- Public / Alternative Financing
- Open for negotiation
Type(s) of Last Financing Round of the project (if Applicable)
- Convertible Loan
Main Service(s) Required
- Financial Services
- Professional Services
Attached files
Organisation
China (Hong Kong)
Similar opportunities
Project
Point-of-care Early Cancer Breath Testing
- No
- Yes
- Debt
- Equity
- Technology
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Minority Shareholdings
- Direct Equity Investment
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- Public / Alternative Financing
- Private Equity & Venture Capital
- Investment / Financing Discussion
Grover Cheung
Founder & CEO at Qi Diagnostics Limited
China (Hong Kong)
Project
Respira | Transforming Air into Human Potential Through Sensory Intelligence
- Yes
- Yes
- IoT
- Debt
- Equity
- Bio-Tech
- Technology
- Bootstrapping
- Private Project
- Convertible Loan
- Financial Services
- Investment Banking
- Property Technology
- Open for negotiation
- Smart City Technology
- New Town Development
- Open for Negotiation
- Hospitality & Tourism
- Minority Shareholdings
- Direct Equity Investment
- 2,500,001 to 5,000,000 USD
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
- Building And Construction Technology
Bernald Leone
Founder & CEO at Respira
Singapore
Project
通用型人类多能干细胞来源胰岛类器官糖尿病根治性疗法 (Off-the-shelf Stem Cell-derived Islet Organoid Therapy for Diabetes Cure)
- No
- Yes
- Equity
- Technology
- Equity (private)
- Financial Services
- Professional Services
- Minority Shareholdings
- Direct Equity Investment
- 25,000,001 to 50,000,000 USD
- 25,000,001 to 50,000,000 USD
- Investment / Financing Discussion
- Public-Private Partnership Project
Yi HE
CTO at 周易生物
China (Hong Kong)